325 related articles for article (PubMed ID: 25736733)
1. High-dose-rate brachytherapy as a monotherapy for prostate cancer--Single-institution results of the extreme fractionation regimen.
Kukiełka AM; Dąbrowski T; Walasek T; Olchawa A; Kudzia R; Dybek D
Brachytherapy; 2015; 14(3):359-65. PubMed ID: 25736733
[TBL] [Abstract][Full Text] [Related]
2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
3. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
4. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
[TBL] [Abstract][Full Text] [Related]
5. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
6. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer.
Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541
[TBL] [Abstract][Full Text] [Related]
7. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
8. High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results.
Prada PJ; Ferri M; Cardenal J; Blanco AG; Anchuelo J; Díaz de Cerio I; Vázquez A; Pacheco M; Raba I; Ruiz S
Brachytherapy; 2018; 17(6):845-851. PubMed ID: 30030111
[TBL] [Abstract][Full Text] [Related]
9. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results.
Zamboglou N; Tselis N; Baltas D; Buhleier T; Martin T; Milickovic N; Papaioannou S; Ackermann H; Tunn UW
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):672-8. PubMed ID: 22929859
[TBL] [Abstract][Full Text] [Related]
10. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate.
Myers MA; Hagan MP; Todor D; Gilbert L; Mukhopadhyay N; Randolf J; Heimiller J; Anscher MS
Brachytherapy; 2012; 11(4):292-8. PubMed ID: 22464911
[TBL] [Abstract][Full Text] [Related]
12. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.
Demanes DJ; Martinez AA; Ghilezan M; Hill DR; Schour L; Brandt D; Gustafson G
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1286-92. PubMed ID: 21310546
[TBL] [Abstract][Full Text] [Related]
13. High dose rate brachytherapy as monotherapy for localised prostate cancer.
Strouthos I; Tselis N; Chatzikonstantinou G; Butt S; Baltas D; Bon D; Milickovic N; Zamboglou N
Radiother Oncol; 2018 Feb; 126(2):270-277. PubMed ID: 29074079
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data.
Ghilezan M; Martinez A; Gustason G; Krauss D; Antonucci JV; Chen P; Fontanesi J; Wallace M; Ye H; Casey A; Sebastian E; Kim L; Limbacher A
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):927-32. PubMed ID: 22197086
[TBL] [Abstract][Full Text] [Related]
16. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
Lee HK; Adams MT; Motta J
Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
[TBL] [Abstract][Full Text] [Related]
17. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.
Rose JN; Crook JM; Pickles T; Keyes M; Morris WJ
Brachytherapy; 2015; 14(3):342-9. PubMed ID: 25727178
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.
Ghadjar P; Keller T; Rentsch CA; Isaak B; Behrensmeier F; Stroux A; Thalmann GN; Aebersold DM
Brachytherapy; 2009; 8(1):45-51. PubMed ID: 19038584
[TBL] [Abstract][Full Text] [Related]
19. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity.
Yoshioka Y; Nose T; Yoshida K; Oh RJ; Yamada Y; Tanaka E; Yamazaki H; Inoue T; Inoue T
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):213-20. PubMed ID: 12694841
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
